HCV 8th Generation
Escherichia Coli.
Sterile Filtered clear solution.
Protein is >95% pure as determined by 12% PAGE (coomassie staining).
Description
The E.Coli derived HCV Eighth generation antigen recombinant mosaic fusion protein contains multiple gene including env – core - NS3 - NS4 – NS5 and covers genotype I, II and III. The protein size is about 80kDa with GST tag at N-terminal
Product Specs
The Hepatitis C Virus (HCV) is a small, enveloped virus measuring 50nm in diameter. Its genetic material consists of a single strand of positive-sense RNA, and it is classified within the Flaviviridae family. HCV is known for its rapid replication rate, producing roughly one trillion viral particles per day in an infected person. This high replication rate, coupled with a lack of proofreading by the HCV RNA polymerase, leads to a significant mutation rate, enabling the virus to evade the host's immune system effectively. HCV is categorized into six genotypes (1-6), with each genotype further divided into subtypes. The distribution and prevalence of these genotypes differ globally. Genotyping plays a crucial role in clinical settings as it helps determine the potential response to interferon-based therapy and the duration of such treatment. Genotypes 1 and 4 demonstrate lower responsiveness to interferon-based therapies compared to genotypes 2, 3, 5, and 6. The HCV 8th generation encompasses a mosaic fusion protein comprising multiple gene cassettes, including env, core, NS3, NS4, and NS5, covering genotypes I, II, and III.
This product consists of an E. coli-derived HCV eighth-generation antigen. It is a recombinant mosaic fusion protein containing multiple genes, including env, core, NS3, NS4, and NS5, covering genotypes I, II, and III. The protein has an approximate size of 80kDa and includes a GST tag at the N-terminal.
This product appears as a clear solution that has been sterilized by filtration.
The HCV 8th generation protein solution is provided at a concentration of 1mg/ml and contains PBS, 25mM K2CO3, and 3M urea.
For short-term storage (up to 2-4 weeks), the product can be stored at 4°C. For extended storage, it is recommended to freeze the product at -20°C. Adding a carrier protein such as 0.1% HSA or BSA is advisable for long-term storage. It is crucial to avoid repeated freezing and thawing of the product.
The purity of the protein in this product is greater than 95%, as determined by 12% PAGE (coomassie staining).
Escherichia Coli.
Product Science Overview
Hepatitis C Virus (HCV) is a significant global health concern, affecting millions of people worldwide. It is an enveloped RNA virus belonging to the Hepacivirus genus of the Flaviviridae family . HCV infection can lead to severe liver diseases, including chronic hepatitis, cirrhosis, and hepatocellular carcinoma . The development of recombinant forms of HCV, particularly the 8th generation, represents a significant advancement in the field of virology and immunology.
HCV has a single-stranded positive-sense RNA genome that encodes a single polyprotein. This polyprotein is processed into at least 11 polypeptides, including three structural proteins (core, and envelope proteins E1 and E2), a small polypeptide named p7, the novel F protein, and six nonstructural (NS) proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) . These proteins play crucial roles in the virus’s life cycle and its ability to evade the host immune system.
The development of recombinant HCV involves the use of genetic engineering techniques to produce viral proteins or particles that can be used for research, diagnostics, and vaccine development. The 8th generation recombinant HCV represents the latest advancements in this field, incorporating multiple viral proteins and molecular tags to enhance its efficacy .
One of the primary applications of recombinant HCV is in the development of vaccines. Despite significant progress in the treatment of HCV with direct-acting antivirals, the development of an effective vaccine remains a critical goal . Recombinant HCV proteins, such as the E1E2 glycoprotein dimer, have shown promise in eliciting strong immune responses . These recombinant proteins can be used to stimulate both cellular and humoral immune responses, providing a potential pathway for the development of a prophylactic vaccine .
The development of recombinant HCV vaccines faces several challenges, including the virus’s high genetic variability and its ability to evade the host immune system . However, recent advancements in genetic engineering and immunology have opened new avenues for research. The use of dendritic cells derived from induced pluripotent stem cells and stimulated by recombinant HCV antigens has shown promise in activating T-lymphocytes and enhancing immune responses .
In conclusion, the 8th generation recombinant HCV represents a significant advancement in the field of virology and immunology. Its development has the potential to contribute to the creation of effective vaccines and improve our understanding of HCV’s interactions with the host immune system. Continued research and innovation in this field are essential for addressing the global health burden posed by HCV.
